Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2020

Open Access 01-12-2020 | Gastric Cancer | Research article

Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer

Authors: Mashiro Okunaka, Daisuke Kotani, Ken Demachi, Akihito Kawazoe, Takayuki Yoshino, Toshikatsu Kawasaki, Kohei Shitara

Published in: BMC Cancer | Issue 1/2020

Login to get access

Abstract

Background

Nanoparticle albumin-bound paclitaxel (nab-PTX) has shown non-inferiority to paclitaxel (PTX) as second-line therapy for advanced gastric cancer (AGC) with fewer infusion-related reactions. The efficacy and safety of nab-PTX plus ramucirumab (RAM) was reported in a phase II trial; however, there is no randomized trial comparing this regimen with PTX plus RAM in patients with AGC. This retrospective study aimed to investigate the efficacy and safety of nab-PTX plus RAM versus PTX plus RAM in patients with AGC.

Methods

This study included patients with AGC who received nab-PTX plus RAM from September 2017 to January 2019 or PTX plus RAM from June 2015 to August 2017 as second-line chemotherapy in our hospital.

Results

A total of 113 and 138 patients who received nab-PTX plus RAM and PTX plus RAM, respectively, were analyzed. Median progression-free survival (PFS) was 3.9 months (95% confidence interval [CI]: 3.4–4.3) in the nab-PTX plus RAM group and 3.9 months (95% CI: 3.1–4.7) in the PTX plus RAM group (hazard ratio [HR]: 1.08; 95% CI: 0.83–1.40; P = 0.573). Median overall survival (OS) was 10.9 months (95% CI: 9.3–12.7) in the nab-PTX plus RAM group and 10.3 months (95% CI: 8.5–12.0) in the PTX plus RAM group (hazard ratio: 0.82; 95% CI: 0.61–1.10; P = 0.188). In patients with moderate/massive ascites, favorable outcomes for progression-free survival were observed in the nab-PTX plus RAM group compared with the PTX plus RAM group. Although anemia and fatigue (any grade) were more frequent in the nab-PTX plus RAM group, discontinuation of study treatment was not increased in the nab-PTX plus RAM group. There was no occurrence of hypersensitivity reaction in the nab-PTX plus RAM group, while two patients (1.4%) experienced grade 3 hypersensitivity reactions in the PTX plus RAM group.

Conclusions

The combination of nab-PTX plus RAM showed a similar efficacy and safety profile to PTX plus RAM as second-line treatment for patients with AGC.
Appendix
Available only for authorised users
Literature
1.
Feely J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, et al. GLOBOCAN 2012 v1.1, cancer incidence and mortality worldwide: IARS cancer base no. 11. Lyon: International Agency for Research on Cancer; 2014.
2.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology gastric cancer. Version 1. 2020.
3.
Japanese Gastric Cancer Association. Japanese gastric cancer treatment guideline 2018 (ver.5).
4.
Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27(5):38–49.CrossRef
5.
Muro K, Van Cutsem E, Narita Y, Pentheroudakis G, Baba E, Li J, et al. Pan-Asian adapted ESMO clinical practice guidelines for the management of patients with metastatic gastric cancer: a JSMO-ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS. Ann Oncol. 2019;30:19–33.CrossRef
6.
Wilke H, Muro K, Van Cutsem CE, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric cancer or gastro-oesophageal junction adenocarcinoma (RAINBOW): adouble-blind, randomized phase 3 trial. Lancet Oncol. 2014;15:1224–35.CrossRef
7.
Shitara K, Muro K, Shimada Y, Hironaka S, Sugimoto N, Komatsu Y, et al. Subgroup aanalysis of the safety and efficacy of ramucirumab in Japanese and Western patients in RAINBOW: a randomised clinical trial in second-line treatment of gastric cancer. Gastric Cancer. 2016;19:927–38.CrossRef
8.
Gelderblom H, Verweij J, Nooter K, Sparreboom A, Cremophor EL. The drawbacks and advantages of vehicle selection for drug formuration. Eur J Cancer. 2001;37:1590–8.CrossRef
9.
Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, et al. Hypersensitivity reactions from taxol. J Clin Oncol. 1990;8:1263–8.CrossRef
10.
Ibrahim NK, Samuels B, Page R, Doval D, Patel KM, Rao SC, et al. Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol. 2005;23:6019–26.CrossRef
11.
Sasaki Y, Nishina T, Yasui H, Goto M, Muro K, Tsuji A, et al. Phase II trial of nanoparticle albumin-bound paclitaxel as second-line chemotherapy for unresectable or recurrent gastric cancer. Cancer Sci. 2014;105:812–7.CrossRef
12.
Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, et al. Nab-paclitaxel versus solvent-based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open-label, randomized, non-inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2:277–87.CrossRef
13.
Bando H, Shimodaira H, Fujitani K, Takashima A, Yamaguchi K, Nakayama N, et al. A phase II study of nab-paclitaxel in combination with ramucirmub in patients with previously treated advanced gastric cancer. Eur J Cancer. 2018;91:86–91.CrossRef
14.
U.S. Department of health and human survices. Common Terminology Criteria for Adverse Events. version 4.03 2010.
15.
Matsumoto H, Kawazoe A, Shimada K, Fukuoka S, Kuboki Y, Bando H, et al. A retrospective study of the safety and efficacy of paclitaxel plus ramucirmab in patients with advanced or recurrent gastric cancer with ascites. BMC Cancer. 2018;18:120.CrossRef
16.
Takashima A, Shitara K, Fujitani K, Koeda K, Hara H, Nakayama N, et al. Peritoneal metastasis as a predictive factor for nab-paclitaxel in patients with pretreated advanced gastric cancer: an exploratory analysis of the phase III ABSOLUTE trial. Gastric Cancer. 2019;22:155–63.CrossRef
17.
Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, et al. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep. 2014;32(1):89–96. https://​doi.​org/​10.​3892/​or.​2014.​3210 Epub 2014 May 23. PMID: 24859429.CrossRefPubMed
18.
Bendell JC, Percent IJ, Weaver RW, Chua CC, Xiong HQ, Cohn AL, et al. phase II study of nab-paclitaxel plus ramucirmab for the second-line treatment of patients with metastatic gastroesophageal cancer. J Clin Oncol. 2020;38:4 suppl 365.
Metadata
Title
Retrospective cohort study of nanoparticle albumin-bound paclitaxel plus ramucirumab versus paclitaxel plus ramucirumab as second-line treatment in patients with advanced gastric cancer
Authors
Mashiro Okunaka
Daisuke Kotani
Ken Demachi
Akihito Kawazoe
Takayuki Yoshino
Toshikatsu Kawasaki
Kohei Shitara
Publication date
01-12-2020
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2020
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-020-07614-6

Other articles of this Issue 1/2020

BMC Cancer 1/2020 Go to the issue

Research article

Influence of Nodal signalling on pluripotency factor expression, tumour cell proliferation and cisplatin-sensitivity in testicular germ cell tumours

Research article

Antagonists of the serotonin receptor 5A target human breast tumor initiating cells

Research article

Clinical effects of curcumin in enhancing cancer therapy: A systematic review

Case report

Sterile, abscess-like cerebral lesion during trastuzumab therapy after HER2 status switch in a triple negative breast cancer patient: a case report and literature review

Research article

A convolutional neural network-based system to classify patients using FDG PET/CT examinations

Research article

Clinical characteristics and prognosis of anal squamous cell carcinoma: a retrospective audit of 144 patients from 11 cancer hospitals in southern China
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits